Verona Pharma to Present Expanded Analysis of Phase 2b COPD Data with Ensifentrine at the American Thoracic Society 2021 International Conference

Posters highlight ensifentrine’s safety profile and its potential to improve lung function and quality of life irrespective of COPD severity

Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces three abstracts highlighting new analyses from Phase 2b clinical trials with nebulized ensifentrine in chronic obstructive pulmonary disease (“COPD”) have been accepted by the American Thoracic Society International Conference (“ATS”) 2021. The abstracts are published on the ATS website and in the peer reviewed publication, American Journal of Respiratory and Critical Care Medicine.

Read more….

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...